EXPLORATION AND QUANTIFICATION OF THE DETERMINANTS OF BASELINE HEALTH-RELATED QUALITY OF LIFE (HRQOL) FOR PATIENTS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Kyriakou, C. [1 ,2 ]
Petrucci, M. [3 ]
Welslau, M. [4 ]
Leleu, X. [5 ]
Vande Broek, I. [6 ]
Bacon, P. [7 ]
Lewis, P. [8 ]
Gilet, H. [9 ]
Arnould, B. [9 ]
Murphy, P. [10 ]
机构：
[1] Northwick Pk Hosp & Clin Res Ctr, London, England
[2] Royal Free Hosp, London, England
[3] Sapienza Univ Rome, Dept Cellular Biotechnol & Hematol, Div Hematol, Rome, Italy
[4] Studienzentrum Hamatol, Aschaffenburg, Germany
[5] CHRU Hop Huriez, Lille, France
[6] AZ Nikolaas, St Niklaas, Belgium
[7] Celgene Int Sarl, Boudry, Switzerland
[8] Celgene GmbH, Munich, Germany
[9] MAPI Consultancy, Lyon, France
[10] Beaumont Hosp, Dublin, Ireland
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
B1502
引用
收藏
页码：600 / 600
页数：1
相关论文
共 50 条
  • [41] Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study
    Cella, David
    McKendrick, Jan
    Kudlac, Amber
    Palumbo, Antonio
    Oukessou, Abderrahim
    Vij, Ravi
    Zyczynski, Teresa
    Davis, Catherine
    ANNALS OF HEMATOLOGY, 2018, 97 (12) : 2455 - 2463
  • [42] Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study
    David Cella
    Jan McKendrick
    Amber Kudlac
    Antonio Palumbo
    Abderrahim Oukessou
    Ravi Vij
    Teresa Zyczynski
    Catherine Davis
    Annals of Hematology, 2018, 97 : 2455 - 2463
  • [43] Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study
    Weisel, Katja
    Paner, Agne
    Engelhardt, Monika
    Taylor, Fiona
    Cocks, Kim
    Popa-McKiver, Mihaela
    Chen, Clara
    Cavo, Michele
    BLOOD, 2019, 134
  • [44] Health-related quality of life and physical activity in patients with multiple myeloma in remission
    Nielsen, Lene Kongsgaard
    Larsen, Rikke Faebo
    Jespersen, Eva
    QUALITY OF LIFE RESEARCH, 2018, 27 : S138 - S138
  • [45] Health state utilities and health-related quality of life (HRQOL) in patients with dysphagia
    Stern, Nick
    Doorley, Edel
    Sarkar, Sanchoy
    Bodger, Keith
    GASTROENTEROLOGY, 2006, 130 (04) : A454 - A454
  • [46] Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
    Ludwig, Heinz
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Mateos, Maria-Victoria
    Kaiser, Martin
    Hajek, Roman
    Feng, Shibao
    Cocks, Kim
    Buchanan, Jaqueline
    Weisel, Katja
    BLOOD CANCER JOURNAL, 2019, 9 (3)
  • [47] Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study
    Schjesvold, Fredrik H.
    Ludwig, Heinz
    Delimpasi, Sossana
    Robak, Pawel
    Coriu, Daniel
    Tomczak, Waldemar
    Pour, Ludek
    Spicka, Ivan
    Dimopoulos, Meletios-Athanasios
    Masszi, Tamas
    Chernova, Natalia G.
    Sandberg, Anna
    Thuresson, Marcus
    Norin, Stefan
    Bakker, Nicolaas A.
    Mateos, Maria-Victoria
    Richardson, Paul G.
    Sonneveld, Pieter
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 2331 - 2336
  • [48] HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    Yount, S.
    Beaumont, J.
    Kaiser, K.
    Wortman, K.
    Chen, S. Y.
    Van Brunt, D.
    Cella, D.
    VALUE IN HEALTH, 2014, 17 (07) : A601 - A601
  • [49] Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study
    Schjesvold, Fredrik H.
    Ludwig, Heinz
    Delimpasi, Sossana
    Robak, Pawel
    Coriu, Daniel
    Tomczak, Waldemar
    Pour, Ludek
    Spicka, Ivan
    Dimopoulos, Meletios-Athanasios
    Masszi, Tamas
    Chernova, Natalia G.
    Sandberg, Anna
    Thuresson, Marcus
    Norin, Stefan
    Bakker, Nicolaas A.
    Mateos, Maria-Victoria
    Richardson, Paul G.
    Sonneveld, Pieter
    HAEMATOLOGICA, 2024, 109 (07) : 2331 - 2336
  • [50] Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
    Heinz Ludwig
    Philippe Moreau
    Meletios A. Dimopoulos
    Maria-Victoria Mateos
    Martin Kaiser
    Roman Hajek
    Shibao Feng
    Kim Cocks
    Jaqueline Buchanan
    Katja Weisel
    Blood Cancer Journal, 9
12345